Cancer Diagnostics – News and Features

Researchers at the German Cancer Research Center (DKFZ) have now developed a method that allows for the first time to reconstruct the temporal development—the evolution—of cancerous cells from a single tissue sample.

A study from the University of Chicago introduces an RNA-based liquid biopsy that detects early-stage colorectal cancer with 95% accuracy. The test overcomes the limitations of DNA-based methods.

While many patients experience long-term benefits from cancer treatment, some will derive no benefit whatsoever. The study examined RNA sequencing data and clinical outcomes from several prostate cancer clinical trial datasets.

The diagnostics landscape has transformed over the last 12 months. In this interview, Mara Aspinall, a leader in diagnostic innovation, policy and partner at Illumina Ventures, reflected on the defining moments of the last year and what lies ahead.

Researchers have developed a bioengineered hydrogel platform capable of preserving patient-derived tumor tissues for longer periods, a breakthrough that could enhance drug testing for abdominal cancer.

Researchers have developed a new class of nanomaterial that helps to manipulate light and improve the sensitivity of biosensors for detecting disease biomarkers.

A new genomic test has been developed to accurately predict whether a patient’s cancer will resist common chemotherapy treatments.

The tech demonstrated the ability to automate tumor segmentation with high consistency across hospitals and scan types.

This article explores how cancer biomarkers improve early detection, guide treatments and predict outcomes to transform personalized cancer care.

Researchers have established a living fallopian tube biobank, utilizing cells and tissues donated by patients, which helps scientists study how ovarian cancer begins — cell by cell — directly in human tissue.